{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:21:33Z","timestamp":1790767293546,"version":"4.1.0"},"reference-count":52,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T00:00:00Z","timestamp":1539216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0204610","type":"journal-article","created":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T17:36:45Z","timestamp":1539279405000},"page":"e0204610","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pulmonary hypertension-targeted therapies in heart failure: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"13","author":[{"given":"Charles-Antoine","family":"Guay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3099-2007","authenticated-orcid":true,"given":"Louis-Vincent","family":"Morin-Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Lacasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Lega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steeve","family":"Provencher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,10,11]]},"reference":[{"issue":"25","key":"ref1","doi-asserted-by":"crossref","first-page":"D34","DOI":"10.1016\/j.jacc.2013.10.029","article-title":"Updated clinical classification of pulmonary hypertension","volume":"62","author":"G Simonneau","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"ref2","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jacc.2008.11.051","article-title":"Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study","volume":"53","author":"CS Lam","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"ref3","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jacc.2011.06.076","article-title":"Pulmonary pressures and death in heart failure: a community study","volume":"59","author":"F Bursi","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"ref4","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1161\/CIRCULATIONAHA.111.085761","article-title":"Pulmonary hypertension due to left heart disease","volume":"126","author":"M Guazzi","year":"2012","journal-title":"Circulation"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1183\/09031936.00074312","article-title":"The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease","volume":"41","author":"R Naeije","year":"2013","journal-title":"Eur Respir J"},{"key":"ref6","article-title":"Pulmonary hypertension due to left heart disease: analysis of survival according to the haemodynamic classification of the 2015 ESC\/ERS guidelines and insights for future changes","author":"M Palazzini","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"13","key":"ref7","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.jacc.2017.01.051","article-title":"Pulmonary Hypertension in Heart Failure: Pathophysiology, Pathobiology, and Emerging Clinical Perspectives","volume":"69","author":"M Guazzi","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1378\/chest.12-1653","article-title":"Diastolic pulmonary vascular pressure gradient: a predictor of prognosis in "out-of-proportion" pulmonary hypertension","volume":"143","author":"C Gerges","year":"2013","journal-title":"Chest"},{"issue":"25","key":"ref9","doi-asserted-by":"crossref","first-page":"D100","DOI":"10.1016\/j.jacc.2013.10.033","article-title":"Pulmonary hypertension due to left heart diseases","volume":"62","author":"JL Vachiery","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S2213-2600(16)00027-8","article-title":"Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis","volume":"4","author":"AC Lajoie","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"22","key":"ref11","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.jacc.2007.07.078","article-title":"Long-term use of sildenafil in the therapeutic management of heart failure","volume":"50","author":"M Guazzi","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"ref12","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1161\/CIRCULATIONAHA.107.716373","article-title":"Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension","volume":"116","author":"GD Lewis","year":"2007","journal-title":"Circulation"},{"issue":"2","key":"ref13","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1086\/681264","article-title":"Use of pulmonary arterial hypertension-approved therapy in the treatment of non-group 1 pulmonary hypertension at US referral centers","volume":"5","author":"AW Trammell","year":"2015","journal-title":"Pulm Circ"},{"key":"ref14","article-title":"Cochrane handbook for systematic reviews of interventions","volume":"xxi","author":"JPT Higgins","year":"2008"},{"issue":"15","key":"ref15","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/eurheartj\/ehx700","article-title":"Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial","volume":"39","author":"J Bermejo","year":"2018","journal-title":"Eur Heart J"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01886-2017","article-title":"Macitentan in pulmonary hypertension due to left ventricular dysfunction","volume":"51","author":"JL Vachiery","year":"2018","journal-title":"Eur Respir J"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"JP Higgins","year":"2011","journal-title":"BMJ"},{"issue":"5","key":"ref18","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/oxfordjournals.aje.a010035","article-title":"Random-effects meta-analyses are not always conservative","volume":"150","author":"C Poole","year":"1999","journal-title":"Am J Epidemiol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"X Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"ref20","first-page":"43","article-title":"[Non-radioimmunometric NT-ProBNP and BNP assays: impact of diluent, age, gender, BMI]","volume":"63","author":"Y Alibay","year":"2005","journal-title":"Ann Biol Clin (Paris)"},{"issue":"5","key":"ref21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jchf.2017.02.021","article-title":"Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the ENABLE Trials","volume":"5","author":"M Packer","year":"2017","journal-title":"JACC Heart Fail"},{"issue":"4","key":"ref22","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"D Moher","year":"2009","journal-title":"Ann Intern Med"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/eurjhf\/hfr147","article-title":"Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study","volume":"14","author":"M Guazzi","year":"2012","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"ref24","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.110.983866","article-title":"Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study","volume":"124","author":"M Guazzi","year":"2011","journal-title":"Circulation"},{"issue":"1","key":"ref25","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCHEARTFAILURE.110.944694","article-title":"PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study","volume":"4","author":"M Guazzi","year":"2011","journal-title":"Circ Heart Fail"},{"issue":"2","key":"ref26","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/chf.12008","article-title":"Is chronic sildenafil therapy safe and clinically beneficial in patients with systolic heart failure?","volume":"19","author":"A Amin","year":"2013","journal-title":"Congest Heart Fail"},{"issue":"9431","key":"ref27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0140-6736(04)16723-8","article-title":"Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial","volume":"364","author":"I Anand","year":"2004","journal-title":"Lancet"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cardfail.2004.05.006","article-title":"Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study","volume":"11","author":"M Packer","year":"2005","journal-title":"J Card Fail"},{"issue":"4","key":"ref29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000107791","article-title":"Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension\u2014a multi-center randomized study","volume":"109","author":"E Kaluski","year":"2008","journal-title":"Cardiology"},{"issue":"2","key":"ref30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jchf.2013.12.002","article-title":"Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction","volume":"2","author":"MR Zile","year":"2014","journal-title":"JACC Heart Fail"},{"key":"ref31","article-title":"Pilot Study of Endothelin Receptor Blockade in Heart Failure with Diastolic Dysfunction and Pulmonary Hypertension (BADDHY-Trial)","author":"B Koller","year":"2016","journal-title":"Heart Lung Circ"},{"issue":"12","key":"ref32","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial","volume":"309","author":"MM Redfield","year":"2013","journal-title":"JAMA"},{"issue":"6","key":"ref33","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.ahj.2015.03.018","article-title":"PDE 5 inhibition with udenafil improves left ventricular systolic\/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; A 12-week, randomized, double-blind, placebo-controlled trial","volume":"169","author":"KH Kim","year":"2015","journal-title":"Am Heart J"},{"issue":"38","key":"ref34","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1093\/eurheartj\/ehv336","article-title":"Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial","volume":"36","author":"ES Hoendermis","year":"2015","journal-title":"Eur Heart J"},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0002-8703(97)70105-4","article-title":"A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST)","volume":"134","author":"RM Califf","year":"1997","journal-title":"Am Heart J"},{"issue":"3","key":"ref36","doi-asserted-by":"crossref","first-page":"34A","DOI":"10.1016\/S0002-9149(99)80381-6","article-title":"Safety and efficacy of epoprostenol in patients with severe congestive heart failure","volume":"75","author":"CA Sueta","year":"1995","journal-title":"Am J Cardiol"},{"issue":"5","key":"ref37","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1161\/CIRCULATIONAHA.113.001458","article-title":"Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study","volume":"128","author":"D Bonderman","year":"2013","journal-title":"Circulation"},{"issue":"21","key":"ref38","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.2015.15734","article-title":"Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial","volume":"314","author":"M Gheorghiade","year":"2015","journal-title":"JAMA"},{"issue":"15","key":"ref39","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/eurheartj\/ehw593","article-title":"Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study","volume":"38","author":"B Pieske","year":"2017","journal-title":"Eur Heart J"},{"issue":"1","key":"ref40","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1136\/hrt.37.1.26","article-title":"Pulmonary vascular changes associated with isolated mitral stenosis in India","volume":"37","author":"HD Tandon","year":"1975","journal-title":"Br Heart J"},{"issue":"2","key":"ref41","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1161\/CIRCULATIONAHA.109.887570","article-title":"Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure","volume":"121","author":"P Meyer","year":"2010","journal-title":"Circulation"},{"issue":"18","key":"ref42","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1093\/eurheartj\/ehq245","article-title":"Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure","volume":"31","author":"T Damy","year":"2010","journal-title":"Eur Heart J"},{"key":"ref43","article-title":"Statistical power analysis for the behavioral sciences","volume":"xxi","author":"J. Cohen","year":"1988"},{"issue":"4","key":"ref44","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ejhf.47","article-title":"Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis","volume":"16","author":"X Wu","year":"2014","journal-title":"Eur J Heart Fail"},{"issue":"13","key":"ref45","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.jacc.2017.08.012","article-title":"Cardiopulmonary Exercise Testing: What Is its Value?","volume":"70","author":"M Guazzi","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"ref46","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/eurheartj\/ehi162","article-title":"Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review","volume":"26","author":"LG Olsson","year":"2005","journal-title":"Eur Heart J"},{"issue":"4","key":"ref47","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1751-7133.2012.00293.x","article-title":"Phosphodiesterase inhibitors, congestive heart failure, and sudden death: time for re-evaluation","volume":"18","author":"A Varma","year":"2012","journal-title":"Congest Heart Fail"},{"issue":"6","key":"ref48","doi-asserted-by":"crossref","first-page":"488","DOI":"10.14740\/jocmr3008w","article-title":"Phosphodiesterase-5 Inhibitors Improve Clinical Outcomes, Exercise Capacity and Pulmonary Hemodynamics in Patients With Heart Failure With Reduced Left Ventricular Ejection Fraction: A Meta-Analysis","volume":"9","author":"R De Vecchis","year":"2017","journal-title":"J Clin Med Res"},{"issue":"1","key":"ref49","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12872-017-0576-4","article-title":"Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials","volume":"17","author":"IC Hwang","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"issue":"3","key":"ref50","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1536\/ihj.16-307","article-title":"Clinical and Hemodynamic Effects of Endothelin Receptor Antagonists in Patients With Heart Failure","volume":"58","author":"B Xiong","year":"2017","journal-title":"Int Heart J"},{"issue":"2","key":"ref51","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.recesp.2016.01.002","article-title":"2015 ESC\/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension","volume":"69","author":"N Galie","year":"2016","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"38","key":"ref52","first-page":"2869","article-title":"Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research","volume":"38","author":"MM Hoeper","year":"2017","journal-title":"Eur Heart J"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0204610","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T08:17:40Z","timestamp":1589012260000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0204610"}},"subtitle":[],"editor":[{"given":"Guy A.","family":"MacGowan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,10,11]]},"references-count":52,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,10,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0204610","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,11]]}}}